NL-OMON39959已完成不适用
Effect of three B-cell inhibitors: rituximab, alemtuzumab and bortezomib on anti-A and/or anti-B titer kinetics. - anti-A/B titers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •age * 18 yr
- •patients should be competent
- •have blood group A,B or O
- •will receive treatment with rituximab, bortezomib, alemtuzumab (prescribed by their hematologist)
排除标准
- •blood group AB
- •having a low antiA/B titer < 1:8
- •treatment with IVIG or plasma in the past three months
研究者
相似试验
招募中
不适用
Influence of B cell depletion therapy (rituximab) on (risk factors of) comorbidity in rheumatoid arthritisrheumatoid arthritis100822061000381610023213NL-OMON31299Vrije Universiteit Medisch Centrum50
进行中（未招募）
不适用
Efficacy of B-cell depletion with rituximab on oral, ocular and general disease manifestations in patients with primary Sjögren diseasePreviously treated patients with primary Sjögrens diseaseMedDRA version: 8.0Level: PTClassification code 10040767EUCTR2005-004740-31-DKniversity of Copenhagen34
已完成
1 期
Initial Study of Rituximab to Treat Primary Biliary CirrhosisPrimary Biliary CirrhosisNCT00364819University of California, Davis6
尚未招募
不适用
Study on the efficacy of rituximab in patients with polymyalgia rheumaticapolymyalgia rheumaticaNL-OMON27507one. This is an investigator initiated trial50
进行中（未招募）
1 期
Comparison of two treatments rituximab in patients with autoimmune disease resistant to conventional treatmentsEUCTR2011-005856-32-ESFundación Progreso y Salud9